A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor...

por Malhi, Vikram, Colburn, Dawn, Williams, Sarah J., Hop, Cornelis E. C. A., Dresser, Mark J., Chandra, Priya, Graham, Richard A.
Publicado no Cancer Chemother Pharmacol (2016)

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

por Couban, Stephen, Benevolo, Giulia, Donnellan, William, Cultrera, Jennifer, Koschmieder, Steffen, Verstovsek, Srdan, Hooper, Gregory, Hertig, Christian, Tandon, Maneesh, Dimier, Natalie, Malhi, Vikram, Passamonti, Francesco
Publicado no J Hematol Oncol (2018)

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects

por Graham, Richard A, Hop, Cornelis E C A, Borin, Marie T, Lum, Bert L, Colburn, Dawn, Chang, Ilsung, Shin, Young G, Malhi, Vikram, Low, Jennifer A, Dresser, Mark J
Publicado em 2012